Showing results (11-20 of 70) with videos related to

Sort By:
Pageof 7
American Journal of Clinical Dermatology|July 3, 2020
Dermatological Toxicities of Bruton's Tyrosine Kinase InhibitorsVincent Sibaud, Marie Beylot-Barry, Caroline Protin, et al.
Frontiers in Immunology|March 18, 2021
Lymphoma Heterogeneity Unraveled by Single-Cell TranscriptomicsLoic Ysebaert, Anne Quillet-Mary, Marie Tosolini, et al.
BMC Geriatrics|June 13, 2020
Hemoglobin concentration; a pathway to frailtyZara Steinmeyer, Cyrille Delpierre, Gaelle Soriano, et al.
American Journal of Clinical Pathology|November 21, 2007
Characterization of bone marrow lymphoid infiltrates after immunochemotherapy for follicular lymphomaCamille Laurent, Geisilene Rusno de Paiva, Loic Ysebaert, et al.
European Journal of Haematology|June 19, 2014
Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patientsLucie Oberic, Willy Vaillant, Benjamin Hebraud, et al.
Cellular & Molecular Immunology|December 18, 2012
What lessons can be learned from γδ T cell-based cancer immunotherapy trials?Jean-Jacques Fournié, Hélène Sicard, Mary Poupot, et al.
Haematologica|October 16, 2012
Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemiaEmmanuelle Bouvet, Cécile Borel, Lucie Obéric, et al.
Open Forum Infectious Diseases|October 30, 2019
Ribavirin for Chronic Hepatitis E Virus Infection in Ibrutinib-Exposed PatientsCaroline Protin, Florence Abravanel, Laurent Alric, et al.
Oncotarget|September 9, 2017
Nurse-like cells promote CLL survival through LFA-3/CD2 interactionsFrédéric Boissard, Marie Tosolini, Laetitia Ligat, et al.
Biomarker Research|December 10, 2020
Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapseSarah Cadot, Carine Valle, Marie Tosolini, et al.
Pageof 7